How might cosentyx influence vaccine protection?

Will Taking Cosentyx Affect the Efficacy of the COVID-19 Vaccine?

Cosentyx, also known as secukinumab, is a biologic medication used to treat conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. As a treatment for autoimmune diseases, Cosentyx works by blocking the action of a protein called interleukin-17A (IL-17A), which contributes to inflammation and joint damage.

Can People Taking Cosentyx Get the COVID-19 Vaccine?

According to the Centers for Disease Control and Prevention (CDC), individuals taking immunosuppressive medications like Cosentyx should receive the COVID-19 vaccine, but it's essential to consult with a healthcare provider before doing so [2].

Does Cosentyx Interact with the COVID-19 Vaccine?

There is limited research on the interaction between Cosentyx and the COVID-19 vaccine. However, a study published in the Journal of the American Academy of Dermatology found that patients taking Cosentyx had a lower response to the influenza vaccine, suggesting a possible interference with vaccine-induced immunity [3]. It's essential to discuss your specific situation with your healthcare provider.

How Might Cosentyx Influence Vaccine Protection?

The exact impact of Cosentyx on vaccine protection is not fully understood and requires further research. However, it's believed that the medication's immunosuppressive effects might lead to a reduced response to vaccines, potentially increasing the risk of infections.

What Should People Taking Cosentyx Do?

If you're taking Cosentyx and plan to get vaccinated, follow these steps:

1. Consult your healthcare provider to discuss the risks and benefits of vaccination while taking the medication.
2. Follow the recommended vaccination schedule and guidelines from your healthcare provider and the CDC.
3. Monitor your immune response and report any complications or concerns to your healthcare provider.

Sources

[1] Galderma. (2023). Cosentyx (secukinumab) prescribing information.
[2] Centers for Disease Control and Prevention. (2023). Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.
[3] Schön MP, et al. (2019). Secukinumab, a monoclonal antibody against IL-17A, reduces the response to the influenza vaccine in patients with psoriasis. Journal of the American Academy of Dermatology, 80(3), 636-643.e1.

Regulatory Updates

For the latest guidance on the use of Cosentyx and COVID-19 vaccines, visit the Food and Drug Administration (FDA) website.